Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

NCT06215950 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT06215950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06215950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
January 10, 2024
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cervix cancer, gynecologic cancer, metastatic cancer, ovarian cancer